Iradimed Co Stock Fundamentals
| IRMD Stock | USD 54.61 0.53 0.96% |
Iradimed Co fundamentals help investors to digest information that contributes to Iradimed's financial success or failures. It also enables traders to predict the movement of Iradimed Stock. The fundamental analysis module provides a way to measure Iradimed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Iradimed stock.
At present, Iradimed's Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 24.2 M, whereas Selling General Administrative is forecasted to decline to about 9.9 M. Iradimed | Select Account or Indicator |
Iradimed Co Company Profit Margin Analysis
Iradimed's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Iradimed Profit Margin | 0.26 % |
Most of Iradimed's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Iradimed Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Iradimed Profit Margin Historical Pattern
Today, most investors in Iradimed Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Iradimed's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's profit margin growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Iradimed profit margin as a starting point in their analysis.
Iradimed Profit Margin |
| Timeline |
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Iradimed Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Iradimed Co has a Profit Margin of 0.2626%. This is 102.34% lower than that of the Health Care Equipment & Supplies sector and 104.81% lower than that of the Health Care industry. The profit margin for all United States stocks is 120.68% lower than that of the firm.
Iradimed Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Iradimed's current stock value. Our valuation model uses many indicators to compare Iradimed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Iradimed competition to find correlations between indicators driving Iradimed's intrinsic value. More Info.Iradimed Co is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.59 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Iradimed Co is roughly 1.69 . At present, Iradimed's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Iradimed by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Iradimed Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iradimed's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iradimed could also be used in its relative valuation, which is a method of valuing Iradimed by comparing valuation metrics of similar companies.Iradimed is currently under evaluation in profit margin category among its peers.
Iradimed Current Valuation Drivers
We derive many important indicators used in calculating different scores of Iradimed from analyzing Iradimed's financial statements. These drivers represent accounts that assess Iradimed's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Iradimed's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 276.4M | 570.5M | 355.4M | 598.3M | 538.4M | 565.4M | |
| Enterprise Value | 229.1M | 511.0M | 299.6M | 550.5M | 495.5M | 520.3M |
Iradimed ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Iradimed's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Iradimed's managers, analysts, and investors.Environmental | Governance | Social |
Iradimed Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 637.46 M | ||||
| Shares Outstanding | 12.67 M | ||||
| Shares Owned By Insiders | 37.30 % | ||||
| Shares Owned By Institutions | 58.57 % | ||||
| Number Of Shares Shorted | 153.03 K | ||||
| Price To Earning | 28.70 X | ||||
| Price To Book | 7.94 X | ||||
| Price To Sales | 9.45 X | ||||
| Revenue | 73.24 M | ||||
| Gross Profit | 56.35 M | ||||
| EBITDA | 21.96 M | ||||
| Net Income | 17.19 M | ||||
| Cash And Equivalents | 55.59 M | ||||
| Cash Per Share | 4.42 X | ||||
| Total Debt | 2.04 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.83 X | ||||
| Book Value Per Share | 6.84 X | ||||
| Cash Flow From Operations | 13.47 M | ||||
| Short Ratio | 4.23 X | ||||
| Earnings Per Share | 1.50 X | ||||
| Price To Earnings To Growth | 4.46 X | ||||
| Target Price | 71.0 | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 692.09 M | ||||
| Total Asset | 92.16 M | ||||
| Retained Earnings | 43.26 M | ||||
| Working Capital | 59.67 M | ||||
| Current Asset | 33.95 M | ||||
| Current Liabilities | 2.89 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 92.16 M | ||||
| Last Dividend Paid | 0.47 |
About Iradimed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iradimed Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iradimed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iradimed Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 3 M | 1.7 M | |
| Total Revenue | 73.2 M | 38.6 M | |
| Cost Of Revenue | 16.9 M | 8.8 M | |
| Sales General And Administrative To Revenue | 0.22 | 0.30 | |
| Research And Ddevelopement To Revenue | 0.04 | 0.06 | |
| Revenue Per Share | 5.78 | 6.07 | |
| Stock Based Compensation To Revenue | 0.03 | 0.04 | |
| Capex To Revenue | 0.11 | 0.12 | |
| Ebit Per Revenue | 0.30 | 0.18 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:Check out Iradimed Piotroski F Score and Iradimed Altman Z Score analysis. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.112 | Dividend Share 0.47 | Earnings Share 1.5 | Revenue Per Share | Quarterly Revenue Growth 0.111 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.